99 related articles for article (PubMed ID: 11685121)
1. Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience.
Grothaus-Pinke B; Günzelmann S; Fauser AA; Kiehl MG
Transplantation; 2001 Oct; 72(8):1456-8. PubMed ID: 11685121
[TBL] [Abstract][Full Text] [Related]
2. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut.
Pihusch R; Salat C; Göhring P; Hentrich M; Wegner H; Pihusch M; Hiller E; Kolb HJ; Ostermann H
Br J Haematol; 2002 May; 117(2):469-76. PubMed ID: 11972534
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
5. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
[TBL] [Abstract][Full Text] [Related]
6. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
7. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation.
Cho BS; Min CK; Kim HJ; Lee S; Kim YJ; Lim JY; Jeong DC; Cho B; Kim HK; Eom KS; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Chung NG
Biol Blood Marrow Transplant; 2010 May; 16(5):629-38. PubMed ID: 19963070
[TBL] [Abstract][Full Text] [Related]
8. Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Imataki O; Nakatani S; Hasegawa T; Kondo M; Ichihashi K; Araki M; Ishida T; Kim SW; Mori S; Fukuda T; Tobinai K; Tanosaki R; Makimoto A; Takaue Y
Am J Hematol; 2006 Oct; 81(10):747-52. PubMed ID: 16865687
[TBL] [Abstract][Full Text] [Related]
9. [A comparison of clinical characteristics and prognosis of adult acute graft-versus-host disease between human leukocyte antigen- identical and -mismatched allogeneic hematopoietic stem cell transplantation].
Zhao X; Xu L; Liu D; Han T; Wang Y; Zhang X; Yan C; Chen H; Han W; Wang J; Zhao T; Li Y; Zhang B; Zhao X; Liu K; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Jan; 53(1):35-9. PubMed ID: 24674726
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
[TBL] [Abstract][Full Text] [Related]
11. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
12. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
13. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.
Lo JW; Leung AY; Huang XR; Lie AK; Metz C; Bucala R; Liang R; Lan HY
Bone Marrow Transplant; 2002 Sep; 30(6):375-80. PubMed ID: 12235522
[TBL] [Abstract][Full Text] [Related]
14. [Analyses of risk factors for intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Yan FH; Wang M; Huang Y; Jiang EL; Ma QL; Wei JL; Pang AM; Zhang RL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1020-3. PubMed ID: 24369157
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
Zhang XH; Liu X; Wang QM; He Y; Zhu XL; Zhang JM; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Fu HX; Chang YJ; Xu LP; Liu KY; Huang XJ
Eur J Haematol; 2018 Feb; 100(2):171-181. PubMed ID: 29114931
[TBL] [Abstract][Full Text] [Related]
16. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
[TBL] [Abstract][Full Text] [Related]
17. Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.
Demesmay K; Tissot E; Bulabois CE; Bertrand MA; Racadot E; Woronoff-Lemsi MC; Cahn JY; Deconinck E
Transplantation; 2002 Oct; 74(8):1190-2. PubMed ID: 12438970
[TBL] [Abstract][Full Text] [Related]
18. Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Zhang X; Zhou Y; Xu L; Han W; Chen H; Chen Y; Fu H; Zhou S; Zhao J; Wang Q; Feng F; Zhu X; Liu K; Huang X
Ann Hematol; 2015 May; 94(5):837-45. PubMed ID: 25512184
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant donor CD4
Rubio MT; Bouillié M; Bouazza N; Coman T; Trebeden-Nègre H; Gomez A; Suarez F; Sibon D; Brignier A; Paubelle E; Nguyen-Khoc S; Cavazzana M; Lantz O; Mohty M; Urien S; Hermine O
Leukemia; 2017 Apr; 31(4):903-912. PubMed ID: 27740636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]